iPremom
Molecular diagnostics company building a first-trimester blood test that predicts pregnancy complications before symptoms appear.
Valencia, Spain
€15M
What They Do
iPremom's platform, MaiRa, analyzes cell-free RNA signals in maternal blood drawn in the first trimester and returns a risk score for complications including preeclampsia. The model was built on more than 26,000 samples linked to roughly 10,000 pregnancies from the PREMOM study, a large Spanish prospective maternity cohort. The test is currently offered through the company's own laboratory in Spain, with EU and US regulatory approval and broader commercial rollout as the stated use of the seed capital.
Competitive Position
Competes against established first-trimester preeclampsia risk tools built on serum biomarkers and against combined-screening algorithms already embedded in some European antenatal pathways. The differentiation claim is cfRNA rather than protein biomarkers, and an unusually large linked prospective cohort for a company at seed stage.
Funding Rounds
No funding rounds on record for this company.